Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
Now Is The Time To Buy This High-Yielding Trio
01:24pm, Saturday, 30'th Aug 2025
The focus of today will be on CMCSA, AES, and SNY. The trifecta provides a reasonably secure 4.5% average yield, an A- average S&P credit rating, and is 33% undervalued. Comcast Corporation could be s
US FDA approves Sanofi's drug for a rare blood disorder
05:56pm, Friday, 29'th Aug 2025
The U.S. Food and Drug Administration has approved Sanofi's drug to treat a type of blood disorder, the company said on Friday, in a sign that the French drugmaker's $3.7 billion bet on the treatment
Press Release: Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
05:50pm, Friday, 29'th Aug 2025
Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA
SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease
10:51am, Friday, 15'th Aug 2025
Sanofi wins EMA's orphan drug status for rilzabrutinib to treat IgG4-RD, a chronic, immune-mediated rare disease.
Press Release: Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease
01:00am, Thursday, 14'th Aug 2025
Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at
Sanofi stops supply of high cholesterol drug to China due to limited availability
06:14am, Tuesday, 12'th Aug 2025
Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French pharmaceuticals firm and its partner Regeneron Pharmaceuticals, in China due to lim
Sanofi: Playing To Win
11:01am, Thursday, 07'th Aug 2025
Sanofi's strategic pivot to immunology and rare diseases, plus AI-driven R&D, targets higher margins and sustainable long-term growth. Blockbuster drugs like Dupixent, Altuviiio, and Beyfortus, alongs
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
01:00am, Wednesday, 06'th Aug 2025
Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”).
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
06:30am, Friday, 01'st Aug 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majori
Sanofi (SNY) Q2 2025 Earnings Call Transcript
04:50pm, Thursday, 31'st Jul 2025
Sanofi (NASDAQ:SNY ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Brian Foard - Executive VP & Head of Specialty Care François-Xavier Roger - Executive VP & CFO Houm
Trump pressures 17 pharma CEOs to cut US drug prices
02:28pm, Thursday, 31'st Jul 2025
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
01:48pm, Thursday, 31'st Jul 2025
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont
Press release: Online availability of Sanofi's half-year financial report for 2025
12:20pm, Thursday, 31'st Jul 2025
Online availability of Sanofi's half-year financial report for 2025 Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
11:41am, Thursday, 31'st Jul 2025
SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.
